



1643

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shuji Ozaki et al.      Art Unit : 1643  
Serial No. : 10/530,696      Examiner : Anne Gussow  
Filed : October 28, 2005      Conf. No. : 1270  
Title : CELL DEATH-INDUCING AGENT

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

English translations of foreign language references AL, AM, AN, AV, and AW are not included, since they are members of the patent family of U.S. references AA, AE, AC, AG, and AH, respectively. English translations of references AX, AY, and AQQ are provided herewith.

Applicants wish to bring to the Examiner's attention co-pending and co-owned non-provisional application serial numbers 10/548,727 (Attorney Docket No. 14875-150US1), 10/550,934 (Attorney Docket No. 14875-151US1), 10/551,504 (Attorney Docket No. 14875-153US1), 10/582,176 (Attorney Docket No. 14875-163US1), 10/582,413 (Attorney Docket No. 14875-164US1), 10/582,304 (Attorney Docket No. 14875-166US1), 11/547,747 (Attorney Docket No. 14875-171US1), and 10/582,654, which concern related subject matter, and some of

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

November 20, 2006  
Date of Deposit

Signature

Scott Barrett  
Typed or Printed Name of Person Signing Certificate

Applicant : Shuji Ozaki et al.  
Serial No. : 10/530,696  
Filed : October 28, 2005  
Page : 2 of 2

Attorney's Docket No.: 14875-141US1 / C1-A0220P-  
US

which have overlapping inventorship with the above-referenced application. Applicants assume that the Examiner has ongoing access to the files of these related applications and can obtain copies of prosecution documents from the files if at any point in the future she considers it potentially relevant to issues in the present application. Applicants will supply copies of such documents from the related applications' files, should the Examiner request them.


This statement is being filed before the receipt of a first Office Action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050.


Respectfully submitted,

Date:

Nov. 20, 2006

  
Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-141US1</b>	Application No. <b>10/530,696</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Shuji Ozaki et al.</b>	
		Filing Date <b>October 28, 2005</b>	Group Art Unit <b>1643</b>

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,877,291	04/20/1995	Mezes et al.			
	AB	6,323,000	11/07/2001	Briggs et al.			
	AC	6,342,220	01/29/2002	Adams et al.			
	AD	6,683,157	01/27/2004	Briggs et al.			
	AE	2001/0006796	07/05/2001	Briggs et al.			
	AF	2002/0193571	12/19/2002	Carter et al.			
	AG	2003/0073161	04/17/2003	Briggs et al.			
	AH	2004/0091475	05/13/2004	Tsuchiya et al.			
	AI	2004/0242847	12/02/2004	Fukushima et al.			
	AJ	2006/0189794	08/24/2006	Tsuchiya et al.			
	AK	2006/0222643	10/05/2006	Tsunoda et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL	JP 7-503622	04/20/1995	Japan			See AA	
	AM	JP 2001/506135	05/15/2001	Japan			See AE	
	AN	JP 2001/513999	09/11/2001	Japan			See AC	
	AO	WO 97/31108	08/28/1997	WIPO			English abstract	
	AP	WO 98/28331	07/02/1998	WIPO				
	AQ	WO 99/02567	01/21/1999	WIPO				
	AR	WO 99/10494	03/04/1999	WIPO				
	AS	WO 01/64713	09/07/2001	WIPO				
	AT	WO 01/66737	09/13/2001	WIPO			English abstract	
	AU	WO 01/79494	10/25/2001	WIPO			English abstract	
	AV	WO 02/33072	04/25/2002	WIPO			See AG	
	AW	WO 02/33073	04/25/2002	WIPO			See AH	
	AX	WO 2004/081048	09/23/2004	WIPO			X	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-141US1	Application No. 10/530,696
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Shuji Ozaki et al.	
		Filing Date October 28, 2005	Group Art Unit 1643

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AY	WO 2004/087763	10/14/2004	WIPO			X	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AZ	Ballmaier et al., "c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia," <i>Blood</i> , 97:139-146 (2001)
	AAA	Brinkmann et al., "FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity," <i>Curr. Opin. Immunol.</i> , 14:569-575 (2002)
	ABB	Bruenke et al., "A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells," <i>Br. J. Haematol.</i> , 125:167-179 (2004)
	ACC	Clark, "CD22, a B Cell-Specific Receptor, Mediates Adhesion and Signal Transduction," <i>J. Immunol.</i> , 150:4715-4718 (1993)
	ADD	Co et al., "A Humanized Antibody Specific for the Platelet Integrin gpIIb/IIIa," <i>J. Immunol.</i> , 152:2968-2976 (1994)
	AEE	Deng et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," <i>Blood</i> , 92:1981-1988 (1998)
	AFF	Ebert et al., "Expression of Metallothionein II in Intestinal Metaplasia, Dysplasia, and Gastric Cancer," <i>Cancer Res.</i> , 60:1995-2001 (2000)
	AGG	Elliott et al., "Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies," <i>J. Biol. Chem.</i> , 271:24691-24697 (1996)
	AHH	Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 94:7509-7514 (1997)
	AII	Goel et al., " <sup>99m</sup> Tc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv's: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma," <i>J. Nucl. Med.</i> , 42:1519-1527 (2001)
	AJJ	Goel et al., "Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application," <i>Cancer Res.</i> , 60:6964-6971 (2000)
	AKK	Hudson et al., "High avidity scFv multimers; diabodies and triabodies," <i>J. Immunol. Methods</i> , 231:177-189 (1999)
	ALL	Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies," <i>J. Mol. Biol.</i> , 330:99-111 (2003)
	AMM	Kortt et al., "Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting," <i>Biomol. Eng.</i> , 18:95-108 (2001)
	ANN	Lebrun et al., "Antibodies to the Extracellular Receptor Domain Restore the Hormone-insensitive Kinase and Conformation of the Mutant Insulin Receptor Valine 382," <i>J. Biol. Chem.</i> , 268:11272-11277 (1993)
	AOO	Li et al., "The Epitope Specificity and Tissue Reactivity of Four Murine Monoclonal Anti-CD22 Antibodies," <i>Cell. Immunol.</i> , 118:85-99 (1989)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-141US1	Application No. 10/530,696
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Shuji Ozaki et al.	
		Filing Date October 28, 2005	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	APP	Matsuoka et al., "A Monoclonal Antibody to the $\alpha 2$ Domain of Murine Major Histocompatibility Complex Class I that Specifically Kills Activated Lymphocytes and Blocks Liver Damage in the Concanavalin A Hepatitis Model," <i>J. Exp. Med.</i> , 198:497-503 (2003)
	AQQ	Nishii, "CD22 antibody therapy," <i>Current Therapy</i> , 20:47-50 (2001) (English translation included)
	ARR	Orita et al., "A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor," <i>Blood</i> , 105:562-566 (2005)
	ASS	Ozaki et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in Human Lymphoid Malignancies," <i>Blood</i> , 102:933a, Abstract No. 3474 (2003)
	ATT	Rossi et al., "Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy," <i>Clin. Cancer Res.</i> , 9:3886s-3896s (2003)
	AUU	Sato et al., "CD22 Is Both a Positive and Negative Regulator of B Lymphocyte Antigen Receptor Signal Transduction: Altered Signaling in CD22-Deficient Mice," <i>Immunity</i> , 5:551-562 (1996)
	AVV	Scheurle et al., "Cancer Gene Discovery Using Digital Differential Display," <i>Cancer Res.</i> , 60:4037-4043 (2000)
	AWW	Smith et al., "Inhibition of T Cell Activation by a Monoclonal Antibody Reactive Against the $\alpha 3$ Domain of Human MHC Class I Molecules," <i>J. Immunol.</i> , 153:1054-1067 (1994)
	AXX	Tahtis et al., "Biodistribution Properties of $^{111}$ Indium-labeled C-Functionalized <i>trans</i> -Cyclohexyl Diethylenetriaminepentaacetic Acid Humanized 3S193 Diabody and F(ab') <sub>2</sub> Constructs in a Breast Carcinoma Xenograft Model," <i>Clin. Cancer Res.</i> , 7:1061-1072 (2001)
	AYY	Tedder et al., "CD22, a B Lymphocyte-Specific Adhesion Molecule That Regulates Antigen Receptor Signaling," <i>Annu. Rev. Immunol.</i> , 15:481-504 (1997)
	AZZ	Thilenius et al., "Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants," <i>Eur. J. Immunol.</i> , 27:1108-1114 (1997)
	AAAA	Xiong et al., "Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody," <i>Cancer Lett.</i> , 177:29-39 (2002)
	ABBB	Xu et al., "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver," <i>Proc. Natl. Acad. Sci. USA</i> , 98:15089-15094 (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	